GlassScriptPhysician profile
Arthur M Powell
NPI 1518942176
$3,981.29
in general payments reported to CMS, 2019-2025
33 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $116 · 2021: $842 · 2022: $873 · 2023: $629 · 2024: $401 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $584.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $487.08 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $386.76 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $339.51 | 2021-2023 | Jardiance, Mounjaro, Trulicity |
| Abbvie INC. | $308.70 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $286.26 | 2020-2025 | |
| Glaxosmithkline, LLC. | $174.19 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $168.59 | 2019-2024 | |
| Dexcom, INC. | $154.69 | 2021-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.05 | 2019-2023 | Spiriva Respimat |
| Otsuka America Pharmaceutical, INC. | $123.10 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $117.22 | 2019-2023 | |
| Amarin Pharma, INC. | $81.76 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.52 | 2021-2023 | |
| Esperion Therapeutics, INC. | $79.16 | 2021-2025 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.44 | 2019-2022 | |
| Exact Sciences Corporation | $56.44 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $53.26 | 2021 | |
| Abbott Laboratories | $37.77 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.28 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $26.99 | 2019-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.76 | 2024 | Clear+Brilliant |
| Corium, LLC | $21.84 | 2024 | Azstarys |
| Vivaquant INC, Dba Rhythm Express | $20.31 | 2024 | Rhythm Express |
| Shield Therapeutics INC | $20.18 | 2025 | |
| Roche Diagnostics Corporation | $19.09 | 2019 | |
| Adlon Therapeutics L.P. | $17.90 | 2021 | |
| Corcept Therapeutics | $17.43 | 2023 | Korlym |
| Bausch Health US, LLC | $14.53 | 2019 | |
| Seqirus USA INC | $14.52 | 2022 | |
| Biomerieux INC | $14.00 | 2025 | Biofire Spotfire Control Station |
| Valeritas, INC. | $13.83 | 2019 | |
| Eisai INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.